Literature DB >> 21494579

Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.

Natarajan Muthusamy1, Heather Breidenbach, Leslie Andritsos, Joseph Flynn, Jeffrey Jones, Asha Ramanunni, Xiaokui Mo, David Jarjoura, John C Byrd, Nyla A Heerema.   

Abstract

Reproducible cytogenetic analysis in CLL has been limited by the inability to obtain reliable metaphase cells for analysis. CpG oligonucleotide and cytokine stimulation have been shown to improve metaphase analysis of CLL cytogenetic abnormalities, but is limited by variability in the cytokine receptor levels, stability and biological activity of the cytokine in culture conditions and high costs associated with these reagents. We report here use of a novel, stable CpG, GNKG168 along with pokeweed mitogen (PWM) and phorbol 12-myristate 13-acetate (PMA) for conventional cytogenetic assessment in CLL. We demonstrate that the combined use of GNKG168+PWM/PMA increased the sensitivity of detection of chromosomal abnormalities compared to PWM/PMA (n=207, odds ratio=2.2, p=0.0002) and GNKG168 (n=219, odds ratio=1.5, p=0.0452). Further, a significant increase in sensitivity to detect complexity ≥3 with GNKG168+PWM/PMA compared to GNKG168 alone (odds ratio 8.0, p=0.0022) or PWM/PMA alone (odds ratio 9.6, p=0.0007) was observed. The trend toward detection of higher complexity was significantly greater with GNKG168+PWM/PMA compared to GNKG168 alone (p=0.0412). The increased sensitivity was mainly attributed to the addition of PWM/PMA with GNKG168 because GNKG168 alone showed no difference in sensitivity for detection of complex abnormalities (p=0.17). Comparison of fluorescence in situ hybridization (FISH) results with karyotypic results showed a high degree of consistency, although some complex karyotypes were present in cases with no adverse FISH abnormality. These studies provide evidence for potential use of GNKG168 in combination with PWM and PMA in karyotypic analysis of CLL patient samples to better identify chromosomal abnormalities for risk stratification.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21494579      PMCID: PMC3073597          DOI: 10.1016/j.cancergen.2010.12.006

Source DB:  PubMed          Journal:  Cancer Genet


  35 in total

1.  Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia.

Authors:  Christine Mayr; Michael R Speicher; David M Kofler; Raymund Buhmann; John Strehl; Raymonde Busch; Michael Hallek; Clemens-Martin Wendtner
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

2.  Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia.

Authors:  Kimberly J Stockero; Stephanie R Fink; Stephanie A Smoley; Sarah F Paternoster; Tait D Shanafelt; Timothy G Call; Clive S Zent; Daniel L Van Dyke; Neil E Kay; Gordon W Dewald
Journal:  Cancer Genet Cytogenet       Date:  2006-04-15

3.  Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel.

Authors:  K S Reddy
Journal:  Br J Haematol       Date:  2006-03       Impact factor: 6.998

4.  Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities.

Authors:  S Struski; C Gervais; C Helias; R Herbrecht; B Audhuy; L Mauvieux
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

5.  Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping.

Authors:  C Haferlach; F Dicker; S Schnittger; W Kern; T Haferlach
Journal:  Leukemia       Date:  2007-09-06       Impact factor: 11.528

6.  Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

Authors:  John C Byrd; John G Gribben; Bercedis L Peterson; Michael R Grever; Gerard Lozanski; David M Lucas; Ben Lampson; Richard A Larson; Michael A Caligiuri; Nyla A Heerema
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

7.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

9.  Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.

Authors:  John C Byrd; Thomas S Lin; James T Dalton; Di Wu; Mitch A Phelps; Beth Fischer; Mollie Moran; Kristie A Blum; Brad Rovin; Michelle Brooker-McEldowney; Sarah Broering; Larry J Schaaf; Amy J Johnson; David M Lucas; Nyla A Heerema; Gerard Lozanski; Donn C Young; Jose-Ramon Suarez; A Dimitrios Colevas; Michael R Grever
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

10.  Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression.

Authors:  Frank Dicker; Susanne Schnittger; Torsten Haferlach; Wolfgang Kern; Claudia Schoch
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

View more
  15 in total

1.  Synergy: karyotypes and mutations in CLL.

Authors:  Lynne V Abruzzo
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

2.  Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.

Authors:  Cecelia R Miller; Amy S Ruppert; Nyla A Heerema; Kami J Maddocks; Jadwiga Labanowska; Heather Breidenbach; Gerard Lozanski; Weiqiang Zhao; Amber L Gordon; Jeffrey A Jones; Joseph M Flynn; Samantha M Jaglowski; Leslie A Andritsos; Kristie A Blum; Farrukh T Awan; Kerry A Rogers; Michael R Grever; Amy J Johnson; Lynne V Abruzzo; Erin K Hertlein; James S Blachly; Jennifer A Woyach; John C Byrd
Journal:  Blood Adv       Date:  2017-08-21

3.  Jumping translocations, a novel finding in chronic lymphocytic leukaemia.

Authors:  Cecelia R Miller; Deborah Stephens; Amy S Ruppert; Frederick Racke; Andrew McFaddin; Heather Breidenbach; Huey-Jen Lin; Kathy Waller; Tammy Bannerman; Jeffrey A Jones; Jennifer A Woyach; Leslie A Andritsos; Kami Maddocks; Weiqiang Zhao; Gerard Lozanski; Joseph M Flynn; Michael Grever; John C Byrd; Nyla A Heerema
Journal:  Br J Haematol       Date:  2015-04-19       Impact factor: 6.998

4.  Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.

Authors:  Paolo Strati; Lynne V Abruzzo; William G Wierda; Susan O'Brien; Alessandra Ferrajoli; Michael J Keating
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-02-11

5.  Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.

Authors:  Philip A Thompson; Susan M O'Brien; William G Wierda; Alessandra Ferrajoli; Francesco Stingo; Susan C Smith; Jan A Burger; Zeev Estrov; Nitin Jain; Hagop M Kantarjian; Michael J Keating
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

6.  Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.

Authors:  Deborah M Stephens; Amy S Ruppert; William G Weirda; Jeffrey A Jones; Jennifer A Woyach; Kami Maddocks; Samantha M Jaglowski; Leslie A Andritsos; Joseph M Flynn; Michael R Grever; Gerard Lozanski; Constantine Tam; Susan O'Brien; Michael J Keating; Natarajan Muthusamy; Lynne V Abruzzo; Nyla A Heerema; John C Byrd
Journal:  Am J Hematol       Date:  2015-10-12       Impact factor: 10.047

7.  Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Authors:  Panagiotis Baliakas; Sabine Jeromin; Michalis Iskas; Anna Puiggros; Karla Plevova; Florence Nguyen-Khac; Zadie Davis; Gian Matteo Rigolin; Andrea Visentin; Aliki Xochelli; Julio Delgado; Fanny Baran-Marszak; Evangelia Stalika; Pau Abrisqueta; Kristina Durechova; George Papaioannou; Virginie Eclache; Maria Dimou; Theodoros Iliakis; Rosa Collado; Michael Doubek; M Jose Calasanz; Neus Ruiz-Xiville; Carolina Moreno; Marie Jarosova; Alexander C Leeksma; Panayiotis Panayiotidis; Helena Podgornik; Florence Cymbalista; Achilles Anagnostopoulos; Livio Trentin; Niki Stavroyianni; Fred Davi; Paolo Ghia; Arnon P Kater; Antonio Cuneo; Sarka Pospisilova; Blanca Espinet; Anastasia Athanasiadou; David Oscier; Claudia Haferlach; Kostas Stamatopoulos
Journal:  Blood       Date:  2019-01-02       Impact factor: 22.113

Review 8.  Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.

Authors:  Ayed O Ayed; Sameer A Parikh
Journal:  Leuk Lymphoma       Date:  2017-11-08

Review 9.  The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors:  S N Malek
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

10.  Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.

Authors:  Samantha M Jaglowski; Amy S Ruppert; Nyla A Heerema; Anissa Bingman; Joseph M Flynn; Michael R Grever; Jeffrey A Jones; Patrick Elder; Steven M Devine; John C Byrd; Leslie A Andritsos
Journal:  Br J Haematol       Date:  2012-07-25       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.